Burning Rock Biotech Ltd. ADR (BNR): Price and Financial Metrics Recent IPO


Burning Rock Biotech Ltd. ADR (BNR) Recent IPO

Today's Latest Price: $28.35 USD

0.18 (-0.63%)

Updated Dec 1 6:55pm

Add BNR to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 143 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

BNR Stock Price Chart Interactive Chart >

Price chart for BNR

BNR Price/Volume Stats

Current price $28.35 52-week high $32.40
Prev. close $28.53 52-week low $18.64
Day low $27.47 Volume 60,100
Day high $29.45 Avg. volume 175,338
50-day MA $27.00 Dividend yield N/A
200-day MA $0.00 Market Cap 2.89B

Burning Rock Biotech Ltd. ADR (BNR) Company Bio


Burning Rock Biotech Ltd. engages in the investment of medical fields. It specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology. The company operates through following segment: central laboratory business, in-hospital business and pharma research and development services. Its products and clinical applications including companion diagnostics for targeted therapy and immunotherapy, benign, malignant tumor diagnosis, minimal residual disease monitoring, tumor recurrence and progression prediction, and tumor susceptibility tests. Burning Rock Biotech was founded by Yu Sheng Han in 2014 and is headquartered in Guangzhou, China.


BNR Latest News Stream


Event/Time News Detail
Loading, please wait...

BNR Latest Social Stream


Loading social stream, please wait...

View Full BNR Social Stream

Latest BNR News From Around the Web

Below are the latest news stories about Burning Rock Biotech Ltd that investors may wish to consider to help them evaluate BNR as an investment opportunity.

Burning Rock Biotech EPS misses by $0.30, beats on revenue

Burning Rock Biotech (BNR): Q2 GAAP EPS of -$0.38 misses by $0.30.Revenue of $15.1M beats by $1.64M.Press Release...

Seeking Alpha | August 11, 2020

Week In Review: China Life Science Announces Deals Worth $1.3 Billion

Deals and Financing Boehringer Ingelheim, a privately-held German biopharma, launched its External Innovation Hub China in Shanghai to increase the company's China R&D partnerships (see story). The Hub will have $508 million to spend over the next five years on China clinical research, expansion of production sites and research partnerships....

ChinaBio Today on Seeking Alpha | July 5, 2020

Read More 'BNR' Stories Here

BNR Price Returns

1-mo -3.51%
3-mo 37.96%
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7052 seconds.